Biodegradable bone implant firm Inion seeks UK listing
This article was originally published in Clinica
A Finnish firm developing biodegradable fixation implants is planning to raise £30m ($56m) through a listing on the UK stock market. Tampere-based Inion, whose implants are being sold around the world through distribution deals with companies including Stryker and B Braun's Aesculap division, expects to have a market capitalisation of around £80-90m after completing a placing of shares with European and other institutional investors in early December.
You may also be interested in...
Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.